A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

The funds will be used to support the advancement of the Chicago biotech’s myasthenia gravis (MG) and type 1 diabetes (T1D ... of concept trial in cystic fibrosis for ETD001, an ENaC blocker ...

MASH is a progressive liver disease characterised by inflammation and fibrosis and is closely linked to obesity and Type 2 diabetes. In a significant interim analysis from a large, phase 3 clinical ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

A recent study found that six cardiometabolic risk groups previously identified in middle-aged individuals can also be applied to older adults without diabetes. Using data from the KORA F4/FF4 study ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

A phenomenon largely ignored since its discovery 100 years ago appears to be a crucial component of diabetic pain, according ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2 ...